drugset
drugset / Trial / NCT07150988

A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

NCT07150988 ↗

Phase 2 Not yet recruiting 150 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.

Timeline

Start
2025-09-26
Primary completion
2026-11-06
Completion
2026-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK44459 Unknown — Oral

Indications

psoriasis